Anaptys Partner Search Boosted By Phase III Skin Disease Success

After disappointments in other indications, notably hidradenitis suppurativa, AnaptysBio has posted positive Phase III results for its IL-36 receptor-targeting monoclonal antibody imsidolimab in generalized pustular psoriasis.

Daniel Faga
CEO Daniel Faga • Source: AnaptysBio

AnaptysBio, Inc. has suffered a series of setbacks in the clinic with imsidolimab but its success in a late-stage trial for a rare but potentially life-threatening form of psoriasis could, it hopes, lead to a lucrative licensing deal. 

Key Takeaways

  • AnaptysBio's imsidolimab will be filed next year for generalized pustular psoriasis

The San Diego, CA-based firm has unveiled positive topline data from the Phase III GEMINI-1 trial evaluating imsidolimab in patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category